date,title,source
Oct-22-18,Why Aduro Biotech Crashed 29.5% Today,Motley Fool
Oct-23-18,Aduro Biotech (ADRO) Q3 Earnings Preview: What's in the Cards?,Zacks
Oct-26-18,Aduro Presents Preclinical Data for Anti-APRIL Antibody BION-1301 for the Treatment of IgA Nephropathy at ASN Kidney Week 2018,GlobeNewswire
Oct-30-18,"Aduro Biotech (ADRO) Reports Q3 Loss, Misses Revenue Estimates",Zacks
Oct-30-18,Aduro Biotech Reports Third Quarter 2018 Financial Results,GlobeNewswire
Oct-31-18,"Aduro (ADRO) Q3 Loss Narrower Than Expected, Revenues Lag",Zacks
Nov-06-18,Aduro to Host and Webcast an Investor Event to Review Data Presented at the 2018 Society for Immunotherapy of Cancer (SITC) Annual Meeting,GlobeNewswire
Nov-09-18,Aduro Biotech Presents Preliminary Results from Ongoing Phase 1 Trials of STING agonist ADU-S100 (MIW815) in Patients with Advanced Solid Tumors or Lymphomas,GlobeNewswire
Dec-03-18,Aduro Biotech and Dana-Farber Cancer Institute Present Preclinical Data Supporting Anti-APRIL Antibody BION-1301 for the Treatment of Multiple Myeloma at the 60th American Society of Hematology Annual Meeting and Exposition,GlobeNewswire
Dec-12-18,Aduro Biotech Data Published in Cell Reports Highlights the Significant Role of the Magnitude of Intratumoral STING Activation by ADU-S100 in Anti-Tumor Immunity,GlobeNewswire
Dec-18-18,Lilly and Aduro Biotech Announce Research Collaboration and License Agreement to Develop Novel Immunotherapies,PR Newswire
Dec-19-18,These 4 Pharma Stocks Are Heating Up,ACCESSWIRE
Dec-19-18,Aduro Stock Surges on STING Activator Deal With Eli Lilly,Zacks
Dec-19-18,"Biotech Stock Roundup: Pipeline Updates From VRTX & AMGN, ADRO Teams Up With LLY",Zacks
Dec-19-18,Today's Research Reports on Trending Tickers: Nektar Therapeutics and Aduro BioTech,ACCESSWIRE
Dec-20-18,"What You Must Know About Aduro BioTech, Inc.s (NASDAQ:ADRO) Financial Strength",Simply Wall St.
Dec-20-18,"The Zacks Analyst Blog Highlights: Amgen, Aduro, Vertex, Evofem and Incyte",Zacks
Dec-20-18,Today's Research Reports on Trending Tickers: Aduro BioTech and Adial Pharmaceuticals,ACCESSWIRE
Dec-24-18,"Health Care Digest: 'Killing off' the JPM Week golden goose, a $75 million complement and more",American City Business Journals
Jan-03-19,Aduro Biotech to Present at the 37th Annual J.P. Morgan Healthcare Conference,GlobeNewswire
Jan-22-19,Vertex's Orkambi Wins EU Nod to Treat Cystic Fibrosis in Kids,Zacks
Jan-24-19,Athersys' (ATHX) MultiStem Cell Therapy Succeeds in Study,Zacks
Jan-24-19,Vertex Terminates COO Ian Smith on Code of Conduct Violation,Zacks
Jan-24-19,Amicus (FOLD) Boasts Strong Pipeline Amid Stiff Competition,Zacks
Jan-25-19,"Is Aduro BioTech, Inc. (NASDAQ:ADRO) A Volatile Stock?",Simply Wall St.
Jan-30-19,Aduro Biotech Announces Strategic Reset,GlobeNewswire
Feb-06-19,Top Ranked Momentum Stocks to Buy for February 6th,Zacks
Feb-07-19,Will Aduro Biotech Continue to Surge Higher?,Zacks
Feb-08-19,"AMAG Q4 Loss Narrower Than Expected, Revenues Lag Estimates",Zacks
Feb-11-19,Zoetis (ZTS) to Report Q4 Earnings: What's in the Cards?,Zacks
Feb-11-19,Merrimack (MACK) Stock Up Year to Date: Is a Rebound Likely?,Zacks
Feb-11-19,Aduro Announces First Patient Dosed in Phase 1 Study of ADU-S100 (MIW815) in Combination with YERVOY (ipilimumab) for the Treatment of Relapsed and Refractory Melanoma,GlobeNewswire
Feb-12-19,Aduro Initiates Dosing in Phase I Melanoma Study on ADU-S100,Zacks
